
Retina Research
The physicians at Orange County Retina are national leaders in clinical trials that bring state-of-the-art therapeutics to their patients.
Our research studies have led to:
- Approval of wet AMD treatments that are now considered Standard Care
- Improved treatments for macular edema associated with Retinal Vein Occlusions
- Enhanced understanding of Diabetic Macular Edema
- Basic science and laboratory benchwork leading to clinical applications
- Development of new instruments and equipment
- More efficient and safer surgical technique
Current Clinical Trials
Wet Age-Related Macular Degeneration
Sponsor: Genentech/Roche
Protocol #: GR40549
Study Name: PORTAL
Protocol Title: Transscleral Photocoagulation Laser Substudy in association with Study GR40549. A multicenter, open-label extension study to evaluate the long-term safety and tolerability of the port delivery system with ranibizumab in patients with neovascular age-related macular degeneration.
Clinical Link: https://clinicaltrials.gov/study/NCT03683251
Sponsor: Genentech/Roche
Protocol #: ML43000
Study Name: BELVEDERE
Protocol Title: A phase IV, multicenter, open-label study to assess corneal endothelial cells in patients with neovascular age-related macular degeneration treated with the port delivery system with ranibizumab (PDS).
Clinical Link: https://clinicaltrials.gov/study/NCT04853251
Sponsor: Abbvie/Regenxbio
Protocol #: RGX-314-2104
Study Name: ATMOSPHERE
Protocol Title: A randomized, partially masked, controlled, phase 2b/3 clinical study to evaluate the efficacy and safety of RGX-314 gene therapy in participants with neovascular age-related macular degeneration (nAMD).
Clinical Link: https://clinicaltrials.gov/study/NCT04567550
Sponsor: Abbvie/Regenxbio
Protocol #: RGX-314-3101
Study Name: ASCENT
Protocol Title: A randomized, partially masked, controlled, phase 3 clinical study to evaluate the efficacy and safety of RGX-314 gene therapy in participants with Neovascular Age-Related Macular Degeneration (nAMD).
Clinical Link: https://clinicaltrials.gov/study/NCT04567550
Sponsor: Abbvie/Regenxbio
Protocol #: RGX-314.5101
Study Name: ABBV-RGX-314 Extension Study
Protocol Title: A long-term follow-up study to evaluate the safety and efficacy of RGX-314 following subretinal administration in participants with neovascular age-related macular degeneration and fellow eye treatment substudy.
Clinical Link: https://clinicaltrials.gov/study/NCT03999801
Sponsor: Roche/Genentech
Protocol #: BP41670
Study Name: BURGUNDY
Protocol Title: A three-part, phase I/II study to investigate the safety, tolerability, pharmacokinetics, and efficacy of zifibancimig following intravitreal administration of multiple ascending doses and continuous delivery from the port delivery in patients with neovascular age-related macular degeneration (nAMD).
Clinical Link: https://clinicaltrials.gov/study/NCT04567303
Sponsor: Ocular Therapeutix
Protocol #: OTX-TKI-2023-AMD-301
Study Name: SOL-1
Protocol Title: A phase 3, multicenter, double-masked, randomized, parallel-group study to evaluate the efficacy and safety of intravitreal OTX-TKI (axitinib implant) in subjects with neovascular age-related macular degeneration (nAMD).
Clinical Link: https://clinicaltrials.gov/study/NCT06495918
Sponsor: Genentech/Roche
Protocol #: MR45638
Study Name: CONSTANCE
Protocol Title: Phase IIIV/IV, multicenter, randomized, open-label, two-arm study to investigate the efficacy, safety and durability of Faricimab administered up to every 24 weeks in patients with neovascular age-related macular degeneration (nAMD).
Clinical Link: https://clinicaltrials.gov/study/NCT06795048
Sponsor: Ocular Therapeutix
Protocol #: OTX-TKI-2023-AMD-303.
Study Name: SOL-R
Protocol Title: A phase 3, multicenter, double-masked, randomized, parallel-group study to evaluate the efficacy and safety of intravitreal OTX-TKI (axitinib implant) in subjects with meovascular age-related macular degeneration (nAMD).
Clinical Link: https://clinicaltrials.gov/study/NCT06495918
Sponsor: 4DMT
Protocol #: 4D-150-C003
Study Name: 4FRONT-1
Protocol Title: A phase 3, randomized, double-masked, active-controlled trial of a single intravitreal injection of 4D-150 in adults with macular neovascularization secondary to age-related macular degeneration (nAMD).
Clinical Link: https://clinicaltrials.gov/study/NCT06864988
Sponsor: AbbVie
Protocol #: M24-528
Study Name: ACHIEVE
Protocol Title: A randomized, controlled, partially masked, phase 3b study to assess the injection burden, dfficacy, safety, and long-term preservation of visual acuity of surabgene lomparvovec (ABBV-RGX-314) in a real-world context in subjects with neovascular age-related macular degeneration (nAMD).
Clinical Link: https://clinicaltrials.gov/study/NCT07007065
Sponsor: Eyebiotech
Protocol #: MK-8748-003
Study Name: TORRONTES
Protocol Title: A randomized, double-masked, multi-center, 3-arm pivotal phase 2/3 study to evaluate the efficacy and safety of intravitreal (IVT) EYE201/MK-8748 compared with intravitreal aflibercept (2mg) in participants with neovascular age-related macular degeneration (NVAMD).
Clinical Link: https://clinicaltrials.gov/study/NCT07496567
Wet Age-Related Macular Degeneration / Branch Retinal Vein Occlusion
Sponsor: Eyebiotech
Protocol #: EYE-RES-104
Study Name: SUPER TUSCAN
Protocol Title: A phase 2 randomized dose-masked study of intravitreal (IVT) EYE103 in participants with neovascular age-related macular degeneration (NVAMD) or macular edema following branch retinal vein occlusion (BRVO).
Clinical Link: https://clinicaltrials.gov/study/NCT07205887
Dry Age-Related Macular Degeneration
Sponsor: Regeneron
Protocol #: R3918-AMD-2326
Study Name: SIENNA
Protocol Title: A multicenter, randomized, double-masked, placebo-controlled phase 3 study of the efficacy, safety, and tolerability of subcutaneously adminsitered pozelimab in combination with cemdisiran or cemdisiran alone in participant with geographic atrophy secondary to age-related macular degeneration.
Clinical Link: https://clinicaltrials.gov/study/NCT06541704
Sponsor: Apellis
Protocol #: APL3007-GA-201
Study Name: GALLOP
Protocol Title: A phase 2, randomized, placebo-controlled, multicenter, masked study to evaluate the efficacy, safety, tolerability, and pharmacodynamics of multidose APL-3007 in combination with Syforvre/pegcetacoplan (APL-2) in patients diagnosed with geographic atrophy secondary to age-related macular degeneration (AMD).
Clinical Link: https://clinicaltrials.gov/study/NCT07215390
Sponsor: Samsara
Protocol #: CDV-SNG-21-001
Study Name: CONCERTO
Protocol Title: A prospective, multicenter clinical study of the Implantable Miniature Telescope, Model SING in patients with central vision impairment associated with end-stage age-related macular degeneration (AMD).
Clinical Link: https://clinicaltrials.gov/study/NCT05941273
Non-Proliferative Diabetic Retinopathy
Sponsor: Ocular Therapeutix
Protocol #: OTX-TKI-2025-NPDR-302
Study Name: HELIOS-3
Protocol Title: A phase 3, multicenter, double-masked, randomized, parallel group study to evaluate the efficacy and safety of intravitreal OTX-TKI (zxitinib Implant) in participants with non-proliferative diabetic retinopathy (NPDR).
Clinical Link: https://clinicaltrials.gov/study/NCT07235085
Diabetic Macular Edema
Sponsor: Genentech/Roche
Protocol #: GR40550
Study Name: PAGODA
Protocol Title: A phase III, multicenter, randomized, visual assessor-masked, active-comparator study of the efficacy, safety, and pharmacokinetics of the port delivery system with ranibizumab in patients with diabetic macular edema (DME).
Clinical Link: https://clinicaltrials.gov/study/NCT04108156
Sponsor: Eyebiotech
Protocol #: EYE-RES-102
Study Name: BRUNELLO
Protocol Title: A phase 2/3, randomized, double-masked, dose-finding, safety and efficacy study comparing 2 doses of EYE103 to anti-VEGF in participants with diabetic macular edema (DME).
Clinical Link: https://clinicaltrials.gov/study/NCT06571045
Sponsor: Eyebiotech
Protocol #: EYE-RES-103
Study Name: BAROLO
Protocol Title: A randomized, double-masked, multi-center, 3-arm pivotal phase 2/3 study to evaluate the efficacy and safety of intravitreal EYE103 compared with intravitreal ranibizumab (0.5 mg) in participants with diabetic macular edema (DME).
Clinical Link: https://clinicaltrials.gov/study/NCT06957080
Sponsor: AbbVie
Protocol #: M23-415
Study Name: NAAVIGATE
Protocol Title: An Operationally Seamless Phase 2b/3, Multicenter, Randomized, Masked, Sham-controlled Study to Evaluate the Efficacy and Safety of Surabgene Lomparvovec (Sura-vec) Delivered via Suprachoroidal Space (SCS) Injection Targeting Subjects with Diabetic Retinopathy without Center Involved-Diabetic Macular Edema (CI-DME).
Clinical Link: https://clinicaltrials.gov/study/NCT07592273
Sponsor: Merck
Protocol #: MK-8748-005
Study Name: SYRAH
Protocol Title: MK8748-005: A Randomized, Double-Masked, Multicenter, 3-Arm, Pivotal Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal (IVT) MK-8748 Compared With Aflibercept (2 mg) in Participants With Diabetic Macular Edema (DME).
Clinical Link: https://clinicaltrials.gov/study/NCT07705607
How to Participate
If you are interested in participating in a clinical trial, you may request an appointment by calling any of our locations. Please call during the following office hours: Monday – Friday from 8:00 am to 5:00 pm
Central Santa Ana, CA
(714) 972-8432
Coastal-North Newport Beach, CA
(949) 646-3242
Coastal-South San Juan Capistrano, CA
(949) 496-0611
South Laguna Hills, CA
(949) 581-3618
North Fullerton, CA
(714) 451 -0801
IBC Meeting Minutes:
https://ibcminutes.com/CA00647/AMM_11.17.2025_CA00647.pdf
http://www.wcgclinical.com/orange1
http://www.wcgclinical.com/orange2

